VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
Titel:
VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
Auteur:
Lu, S. Wu, L. Jian, H. Cheng, Y. Wang, Q. Fang, J. Wang, Z. Hu, Y. Sun, M. Han, L. Miao, L. Ding, C. Cui, J. Li, B. Li, X. Wang, K. Cang, S. Pan, Y. Ye, F. Liu, A.